TSVT vs. TYRA, OCUL, ABVX, SPRY, IMNM, IRON, CNTA, CVAC, ARCT, and ETNB
Should you be buying 2seventy bio stock or one of its competitors? The main competitors of 2seventy bio include Tyra Biosciences (TYRA), Ocular Therapeutix (OCUL), ABIVAX Société Anonyme (ABVX), ARS Pharmaceuticals (SPRY), Immunome (IMNM), Disc Medicine (IRON), Centessa Pharmaceuticals (CNTA), CureVac (CVAC), Arcturus Therapeutics (ARCT), and 89bio (ETNB). These companies are all part of the "pharmaceutical preparations" industry.
2seventy bio (NASDAQ:TSVT) and Tyra Biosciences (NASDAQ:TYRA) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, community ranking, analyst recommendations, valuation, profitability, risk, institutional ownership and media sentiment.
In the previous week, Tyra Biosciences had 4 more articles in the media than 2seventy bio. MarketBeat recorded 5 mentions for Tyra Biosciences and 1 mentions for 2seventy bio. 2seventy bio's average media sentiment score of 1.89 beat Tyra Biosciences' score of 1.28 indicating that 2seventy bio is being referred to more favorably in the media.
Tyra Biosciences has a net margin of 0.00% compared to 2seventy bio's net margin of -313.51%. Tyra Biosciences' return on equity of -28.61% beat 2seventy bio's return on equity.
Tyra Biosciences has lower revenue, but higher earnings than 2seventy bio. Tyra Biosciences is trading at a lower price-to-earnings ratio than 2seventy bio, indicating that it is currently the more affordable of the two stocks.
2seventy bio presently has a consensus target price of $12.86, suggesting a potential upside of 203.95%. Tyra Biosciences has a consensus target price of $23.50, suggesting a potential upside of 44.88%. Given 2seventy bio's higher probable upside, research analysts clearly believe 2seventy bio is more favorable than Tyra Biosciences.
2seventy bio has a beta of 1.87, suggesting that its stock price is 87% more volatile than the S&P 500. Comparatively, Tyra Biosciences has a beta of 1.08, suggesting that its stock price is 8% more volatile than the S&P 500.
93.9% of 2seventy bio shares are held by institutional investors. Comparatively, 84.1% of Tyra Biosciences shares are held by institutional investors. 7.2% of 2seventy bio shares are held by company insiders. Comparatively, 15.4% of Tyra Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
2seventy bio received 7 more outperform votes than Tyra Biosciences when rated by MarketBeat users. However, 62.07% of users gave Tyra Biosciences an outperform vote while only 60.98% of users gave 2seventy bio an outperform vote.
Summary
2seventy bio and Tyra Biosciences tied by winning 9 of the 18 factors compared between the two stocks.
Get 2seventy bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for TSVT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TSVT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
2seventy bio Competitors List
Related Companies and Tools
